Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Protagenic Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 18 | 10 | −8 |
| SharesConverted for a 1-for-4 split | 152.9K | 95.4K | −57.4K (−37.6%) |
| Value | $247.9K | $164.2K | −$83.7K (−33.8%) |
New holders (0)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
None.
Sold out (8)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Citadel Advisors LLC | 23,482 | $9.81K |
| Northern Trust Corp | 22,485 | $8.99K |
| Warberg Asset Management LLC | 20,000 | $8.00K |
| Concorde Asset Management, LLC | 16,718 | $6.69K |
| Susquehanna International Group, LLP | 13,977 | $5.84K |
| Virtu Financial LLC | 10,110 | $4.00K |
| Harbor Investment Advisory, LLC | 1 | $0 |
| CWM, LLC | 3 | $0 |